Ipswich Hospital NHS Trust, Ipswich, Suffolk, UK.
Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207. doi: 10.1586/era.09.189.
Review of the spectrum of breast cancer tumor subtypes, which include basal-like, triple-negative and BRCA1-positive tumors, suggest that they have overlapping clinical, pathologic and molecular features, which are different from endocrine responsive breast cancers. Although response to chemotherapy is high in the neoadjuvant setting, the overall prognosis of this subset of tumors remains poor. Gene-profiling studies of this heterogeneous subset have lead to a better understanding of the molecular pathology of these aggressive tumors and the identification of possible therapeutic targets. Ongoing clinical studies of newer targeted agents, along with optimal chemotherapy, portend an improved clinical outcome for patients with aggressive basal-like/triple-negative breast cancer in the future.
乳腺癌肿瘤亚型的研究综述，包括基底样型、三阴性和 BRCA1 阳性肿瘤，表明它们具有重叠的临床、病理和分子特征，与内分泌反应性乳腺癌不同。尽管新辅助化疗的反应率较高，但这组肿瘤的总体预后仍然较差。对这种异质性亚组的基因谱研究，使人们更好地了解了这些侵袭性肿瘤的分子病理学，并确定了可能的治疗靶点。正在进行的新型靶向药物的临床研究，以及最佳化疗，预示着未来侵袭性基底样/三阴性乳腺癌患者的临床结局将得到改善。
